uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

Key Points

• uniQure reported adjusted EPS of ($0.85), beating estimates of ($0.88) while revenue missed at $3.56 million versus $4.49 million, and the quarter showed a very negative net margin and return on equity.
• Major pipeline and regulatory moves include a scheduled Type B meeting with the FDA this quarter and a planned U.K. MAA submission in Q3
• uniQure ended Q1 with $586.6 million in cash—management says this funds operations into H2 2029 but will require prioritization—while the stock trades around $20.26 with a consensus “Moderate Buy” and notable insider selling in recent months.

uniQure (NASDAQ:QURE - Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03, FiscalAI reports. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $4.49 million.

Here are the key takeaways from uniQure's conference call:

• uniQure has a scheduled Type B meeting with the FDA later this quarter to discuss the statistical analysis plan for the 4‑year AMT‑130 data and design elements of a new study, and plans a MAA submission in the U.K. in Q3 based on 3‑year data, creating near‑term regulatory catalysts.
• Enrollment in the Phase I/II‑A study of AMT‑260 for refractory mesial temporal lobe epilepsy is on track, with safety, tolerability and seizure‑frequency results from the first 6‑patient cohort (≥6 months) expected in Q2 and the company targeting a meaningful seizure‑reduction signal to guide dose selection.
• AMT‑191 (Fabry) showed dose‑dependent, durable increases in alpha‑gal A and all 11 dosed patients have discontinued enzyme replacement therapy, but dosing at mid/high cohorts was paused after two asymptomatic grade‑3 liver enzyme elevations and the program is continuing follow‑up while dosing at the low dose.
• The company has discontinued development of AMT‑162 for SOD1‑ALS after a serious adverse event of dorsal root ganglia toxicity in one patient, and will continue safety follow‑up for the five dosed patients.
• uniQure ended Q1 with $586.6 million in cash, equivalents and investments and states this is sufficient to fund operations into H2 2029, though management noted future prioritization will be required to preserve the runway.

uniQure Stock Performance

uniQure stock traded down $0.42 during mid-day trading on Tuesday, reaching $20.26. The company had a trading volume of 435,624 shares, compared to its average volume of 2,824,122. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a 50 day moving average of $16.75 and a 200-day moving average of $25.53. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -5.88 and a beta of 0.87.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on QURE. Leerink Partners restated an "outperform" rating and set a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday, March 10th. Barclays dropped their price target on shares of uniQure from $31.00 to $25.00 and set an "equal weight" rating on the stock in a research note on Monday, March 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, Sanford C. Bernstein lowered shares of uniQure to a "market perform" rating in a research note on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $43.33.

Insider Transactions at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares of the company's stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 14,581 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares of the company's stock, valued at $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 49,396 shares of company stock valued at $722,734. Company insiders own 4.79% of the company's stock.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtus Investment Advisers LLC lifted its holdings in shares of uniQure by 91.6% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company's stock worth $326,000 after acquiring an additional 6,520 shares during the period. SummitTX Capital L.P. lifted its holdings in shares of uniQure by 386.3% during the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company's stock worth $663,000 after acquiring an additional 22,010 shares during the period. Suvretta Capital Management LLC bought a new position in shares of uniQure during the 4th quarter worth about $29,116,000. Readystate Asset Management LP bought a new position in shares of uniQure during the 4th quarter worth about $8,652,000. Finally, Orbimed Advisors LLC lifted its holdings in shares of uniQure by 60.8% during the 4th quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company's stock worth $17,646,000 after acquiring an additional 278,900 shares during the period. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.